Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk

Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial

(2012) Thomas F. Lüscher et al.   EUROPEAN HEART JOURNAL

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

(2012) Benjamin F Voight et al.   LANCET

Structural basis of transfer between lipoproteins by cholesteryl ester transfer protein

(2012) Lei Zhang et al.   Nature Chemical Biology

Single dose pharmacokinetics, pharmacodynamics, tolerability and safety of BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein

(2011) Michael-Friedrich Boettcher et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Effect of Torcetrapib on Glucose, Insulin, and Hemoglobin A 1c in Subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial

(2011) Philip J. Barter et al.   CIRCULATION

Torcetrapib impairs endothelial function in hypertension

(2011) Branko Simic et al.   EUROPEAN HEART JOURNAL

Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL Cholesterol

(2011) Stephen J. Nicholls et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure

(2011) Guoqing Cao et al.   JOURNAL OF LIPID RESEARCH

Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters

(2011) Jose Castro-Perez et al.   JOURNAL OF LIPID RESEARCH

Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib

(2011) Ronald M. Krauss et al.   JOURNAL OF LIPID RESEARCH

Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial

(2011) Zahi A Fayad et al.   LANCET

Cholesterol Efflux Potential and Antiinflammatory Properties of High-Density Lipoprotein After Treatment With Niacin or Anacetrapib

(2010) Laurent Yvan-Charvet et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Effects of High-Density Lipoproteins on Pancreatic β-Cell Insulin Secretion

(2010) Michelle A. Fryirs et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels

(2010) Roger G Clerc et al.   JOURNAL OF HYPERTENSION

Biochemical characterization of cholesteryl ester transfer protein inhibitors

(2010) Mollie Ranalletta et al.   JOURNAL OF LIPID RESEARCH

Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport

(2010) Eric J. Niesor et al.   JOURNAL OF LIPID RESEARCH

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease

(2010) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome

(2009) Gregory G. Schwartz et al.   AMERICAN HEART JOURNAL

Lessons Learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial

(2009) Philip Barter   AMERICAN JOURNAL OF CARDIOLOGY

Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats

(2009) ESG Stroes et al.   BRITISH JOURNAL OF PHARMACOLOGY

High-Density Lipoprotein Modulates Glucose Metabolism in Patients With Type 2 Diabetes Mellitus

(2009) Brian G. Drew et al.   CIRCULATION

Separating the Mechanism-Based and Off-Target Actions of Cholesteryl Ester Transfer Protein Inhibitors With CETP Gene Polymorphisms

(2009) Reecha Sofat et al.   CIRCULATION

Polymorphism in the CETP Gene Region, HDL Cholesterol, and Risk of Future Myocardial Infarction

(2009) Paul M. Ridker et al.   Circulation-Cardiovascular Genetics

The hypertension peril: Lessons from CETP inhibitors

(2009) Matthias Hermann et al.   CURRENT HYPERTENSION REPORTS

Torcetrapib Induces Aldosterone and Cortisol Production by an Intracellular Calcium-Mediated Mechanism Independently of Cholesteryl Ester Transfer Protein Inhibition

(2009) Xiao Hu et al.   ENDOCRINOLOGY

Major Lipids, Apolipoproteins, and Risk of Vascular Disease

(2009) The Emerging Risk Factors Collaboration*   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone

(2008) M J Forrest et al.   BRITISH JOURNAL OF PHARMACOLOGY

Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis

(2008) Stephen J. Nicholls et al.   CIRCULATION

Association of Cholesteryl Ester Transfer Protein Genotypes With CETP Mass and Activity, Lipid Levels, and Coronary Risk

(2008) Alexander Thompson   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The metabolism and anti-atherogenic properties of HDL

(2008) Kerry-Anne Rye et al.   JOURNAL OF LIPID RESEARCH